Lancet Gastroenterology & Hepatology

Papers
(The H4-Index of Lancet Gastroenterology & Hepatology is 72. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-04-01 to 2025-04-01.)
ArticleCitations
Double Duty1184
Correction to Lancet Gastroenterol Hepatol 2022; 7: 152–60416
ESWL pancreatitis: yet another post-procedural pancreatitis to worry about?403
Stringent criteria for withdrawal of biologics in ulcerative colitis – Authors' reply397
Improving liver cancer care across Europe370
Interim evaluation of the colorectal cancer screening programme in the Netherlands359
Trends in alcohol-specific deaths in the UK and industry responses332
Global burden of occult hepatitis B virus infection: where we are and what to do314
Procalcitonin-guided reduction of antibiotic use in acute pancreatitis302
Comparison of trends in early-onset colorectal cancer in North America and Europe – Authors' reply280
Comparison of trends in early-onset colorectal cancer in North America and Europe238
Standardising early liver transplantation for severe alcohol-related hepatitis – Authors' reply237
Disparities in gastroenterology grand rounds speakerships in the USA230
USPSTF: colorectal cancer screening in the US from 45 years225
Challenging stigma around alcohol misuse194
Research in Brief193
Representation and reporting of diverse groups in randomised controlled trials of pharmacological agents in inflammatory bowel disease: a systematic review190
Aspirin after completion of standard adjuvant therapy for colorectal cancer (ASCOLT): an international, multicentre, phase 3, randomised, double-blind, placebo-controlled trial185
Correction to Lancet Gastroenterol Hepatol 2021; 6: 875184
Global epidemiology of acute kidney injury in hospitalised patients with decompensated cirrhosis: the International Club of Ascites GLOBAL AKI prospective, multicentre, cohort study181
AJM300 (carotegrast methyl), an oral antagonist of α4-integrin, as induction therapy for patients with moderately active ulcerative colitis: a multicentre, randomised, double-blind, placebo-controlled174
Management of pouch neoplasia: consensus guidelines from the International Ileal Pouch Consortium173
Virtual ESMO World Congress on Gastrointestinal Cancer 2021172
Outcomes of minimum unit pricing for alcohol in Scotland172
A personalised taper-to-target strategy with adalimumab in Crohn's disease169
Immune checkpoint inhibitors in colorectal cancer: dream and reality164
Viral hepatitis in Asia-Pacific: a post-COVID-19 reset160
Research in Brief156
The quest for the ideal NASH biomarker155
Predicting clinical outcomes in people with NAFLD: no need for a crystal ball?143
Correction to Lancet Gastroenterol Hepatol 2021; 6: 933–46136
Alcohol-related harms and the case for minimum unit pricing128
Vedolizumab in paediatric IBD: a huge step forward but not there yet124
Flux Gourmet: a visual feast with a starved social mission124
Séverine Vermeire: advancing patient-centred research in IBD123
Living121
Peroral endoscopic myotomy versus pneumatic dilation in treatment-naive patients with achalasia – Authors' reply121
Faecal microbiota transplantation for first and second episodes of Clostridioides difficile infection119
Uncoupler therapy for NAFLD: is flushing a possible harbinger of a safety concern?111
Ingestion of high-power magnets: cause for concern108
Correction to Lancet Gastroenterol Hepatol 2021; 6: 569–77107
Launch of the UN Group of Friends to eliminate hepatitis106
Research in Brief104
The Liver Meeting 2023100
Endoscopic screening for oesophageal cancer: empowering artificial intelligence with a high-quality examination98
Research in Brief96
Efficacy and safety of gluten peptide-based antigen-specific immunotherapy (Nexvax2) in adults with coeliac disease after bolus exposure to gluten (RESET CeD): an interim analysis of a terminated rand94
A whole-food exclusion diet as monotherapy for Crohn's disease93
New WHO guidance for country validation of viral hepatitis B and C elimination93
Research in Brief91
Treatment strategies and biomarkers in Crohn's disease: the PROFILE trial90
Reducing disparities in training in inflammatory bowel disease90
The HEPSANET score to assess treatment eligibility of chronic hepatitis B in Africa90
Peroral endoscopic myotomy versus pneumatic dilation in treatment-naive patients with achalasia: 5-year follow-up of a randomised controlled trial89
The role of ERAS in robotic pancreaticoduodenectomy – Authors' reply89
Ranking treatments in the network meta-analysis should consider the certainty of evidence – Authors' reply86
The Other Dark Matter85
Oral faecal microbiota transplantation in ulcerative colitis – Authors' reply85
Can genetically engineered pig livers offer patients precious time?84
Research in Brief84
Gavi's green light for hepatitis B birth dose vaccination in Africa82
Oral faecal microbiota transplantation in ulcerative colitis82
Time to scale up testing and treatment for HBV and HCV in the WHO Eastern Mediterranean Region81
Simplifying the path to elimination of hepatitis C80
ECCO'2479
Closing the gender gap in gastroenterology leadership: the need for effective and comprehensive allyship79
Haematopoietic stem-cell transplantation in Crohn's disease78
17th Congress of ECCO77
Crunching the numbers for viral hepatitis77
Treatment withdrawal in Crohn's disease: slowly becoming clearer74
Global differences in the management of alcohol-associated hepatitis74
Giada Sebastiani: a leading voice on liver fibrosis73
Seeing C diff differently72
Mystery outbreak of severe acute hepatitis in children72
0.033252000808716